Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Safety and Effectiveness of Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Author(s): Ardra Thottarath Prasanthan, Dona Raju, Syamaprasad Thachethukunnil Vinayakumar, Mary Jacob, Anand Chandran, Meenu Vijayan* and Pavithran Keechilatu

Volume 18, Issue 2, 2022

Published on: 22 June, 2022

Page: [148 - 151] Pages: 4

DOI: 10.2174/1573394718666220330103624

Price: $65

Abstract

Background: Hepatocellular carcinoma (HCC) is the most prevalent kind of primary liver cancer and a significant cause of cancer-related mortality across the world. Sorafenib is considered the approved drug of choice in advanced HCC, which is an oral multikinase inhibitor with effective antiproliferative and antiangiogenic effects. In India, there is currently insufficient data on the safety and efficacy of sorafenib in the treatment of HCC.

Objective: The study aims to evaluate the safety and effectiveness of sorafenib therapy in advanced HCC.

Methods: A prospective study of 66 patients administered with sorafenib for advanced HCC between June 2016 and May 2017 was carried out in a single center with a mean follow-up of 3 months. The adverse events (AEs) were graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Effectiveness was analyzed based on alpha-fetoprotein (AFP) levels from laboratory findings. The median age was 63 years (range 61-70), with the male to female ratio of 16:1.

Results: The most commonly observed adverse events were fatigue (31.81%), hand-foot syndrome (24.24%), and diarrhea (24.24%). A statistically significant decline in AFP levels was observed with sorafenib treatment (p= <0.001).

Conclusion: Sorafenib appears to be beneficial for individuals with advanced HCC, regardless of the baseline condition.

Keywords: Hepatocellular carcinoma, sorafenib, alpha feto-protein, adverse event, antiangiogenic effects, hepatic malignancies.

« Previous Next »
Graphical Abstract

[1]
Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: Consider the population. J Clin Gastroenterol 2013; 47(Suppl.): S2-6.
[http://dx.doi.org/10.1097/MCG.0b013e3182872f29] [PMID: 23632345]
[2]
Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: Natural history, current management, and emerging tools. Biologics 2012; 6: 207-19.
[PMID: 22904613]
[3]
Balogh J, Victor D III, Asham EH, et al. Hepatocellular carcinoma: A review. J Hepatocell Carcinoma 2016; 3: 41-53.
[http://dx.doi.org/10.2147/JHC.S61146] [PMID: 27785449]
[4]
Shiozawa K, Watanabe M, Ikehara T, et al. Evaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography. J Med Ultrason (2001) 2017; 44(1): 101-7.
[5]
He AR, Goldenberg AS. Treating hepatocellular carcinoma progression following first-line sorafenib: Therapeutic options and clinical observations. Therap Adv Gastroenterol 2013; 6(6): 447-58.
[http://dx.doi.org/10.1177/1756283X13498540] [PMID: 24179481]
[6]
Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24(26): 4293-300.
[http://dx.doi.org/10.1200/JCO.2005.01.3441] [PMID: 16908937]
[7]
Bai W, Bai W, Wang Y, et al. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unre-sectable hepatocellular carcinoma: A propensity score matching study: Sorafenib and TACE for HCC. J Dig Dis 2013; 14(4): 181-90.
[8]
Sacco R, Bargellini I, Ginanni B, et al. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: What can we learn from routine clinical practice? Expert Rev Anticancer Ther 2012; 12(7): 869-75.
[http://dx.doi.org/10.1586/era.12.58] [PMID: 22845401]
[9]
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378-90.
[http://dx.doi.org/10.1056/NEJMoa0708857] [PMID: 18650514]
[10]
Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: A non-randomised phase 2 clinical trial. Lancet Oncol 2015; 16(1): 98-107.
[http://dx.doi.org/10.1016/S1470-2045(14)71136-2] [PMID: 25498219]
[11]
Chang W-T, Lu S-N, Rau K-M, Huang C-S, Lee K-T. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients. Kaohsiung J Med Sci 2018; 34(7): 391-9.
[http://dx.doi.org/10.1016/j.kjms.2018.03.006] [PMID: 30063012]
[12]
Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol 2012; 57(1): 101-7.

Rights & Permissions Print Cite
Article Metrics
11
© 2024 Bentham Science Publishers | Privacy Policy